Obama’s crusade to make US healthcare work efficiently and effectively
Sending...
18 February 2009 | Published by Datamonitor
London - The Democrats are now in the White House and widespread changes are anticipated for US healthcare and ultimately for Pharma. President Obama’s proposed changes of universal healthcare coverage, continued support of R&D tax credits and increased investment in scientific technology and personalized medicine are all positive for Pharma revenue.
Notes to editors
Notes & References
* The seven major markets are France, Germany, Italy, Japan, Spain, UK and US. ** The donut hole – when a beneficiary has reached the limit of $2,510 and must pay for their drugs until they reach $4,050 in out of pocket expenses before the can be reimbursed for further medication *** Estimates based on 2008 IMS data (IMS health forecast 4.4–4.5 percent growth for global pharmaceutical market in 2009, exceeding $820 bn, 2008: www.ims.com). **** Comparative effectiveness is the comparison of the clinical effectiveness of a drug, device, procedure and diagnostics against alternative equivalent treatments. 1. Income, poverty and health insurance coverage in the United States: 2007, U.S. Census Bureau, 2007: www.census.gov. 2. Keehan, S. et al., 2008 3. Poisal et al., 2007: www.nchc.org. 4. US Census Bureau, 2006: www.census.gov. 5. Why Americans pay more for health care, 2008: www.mckinseyquaterly.com. 6. US Congressional Budget Office, 2006: www.cbo.gov. 7. Healthcare policy in an Obama administration, 2008: www.pwc.com. 8. Obama signs children's health initiative into law, 2009: www.cnn.com. 9. Changing part D Donut hole a “very expensive fix” Daschle notes, 2009: www.thepinksheet.com. 10. IMS Health reports annual global generics prescription sales growth of 3.6 percent to $78 bn, 2009: http://biz.yahoo.com. 11. National coalition on healthcare, 2009: www.nchc.org. 12. FDA budget needs to double over the next five years says science board, 2008; www.fdalegislativewatch.com. 13. Eye on the election, 2008: www.creditsuisse.com.
Further Information
Datamonitor pharmaceutical senior analyst Dr. Sandra Reynolds is available for comment.
More information is available from the Datamonitor Group Media Team. Please contact Matthew Dick on +44 20 7675 7824 or mdick@datamonitor.com.
For US, please contact Alan Sott on +1 570 687 9315.
For Asia-Pacific, please contact Denis Mason on +61 2 8705 6903.
About Datamonitor
Datamonitor is a leading provider of online database and analysis services for key industry sectors. We help our clients, 5000 of the world's leading companies, to address complex strategic issues. Through our proprietary databases and wealth of expertise, we provide clients with unbiased expert analysis and in-depth forecasts for seven industry sectors: Automotive, Consumer Markets, Energy, Financial Services, Pharmaceuticals and Healthcare, Technology, Transport and Logistics.
